Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 19/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 2/20 | 1.00 |
| ▸ | TCF7 | P36402 | 2/20 | 1.00 |
| ▸ | BCL9 | O00512 | 1/20 | 1.00 |
| ▸ | TCF4 | P15884 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19833048 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL13744871 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865605 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677335 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL4865597 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL29352986 | 1.00 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL15677334 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL18699677 | 0.96 | CLPP (1.00) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL19833044 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 | |
| SCHEMBL20752946 | 0.94 | CLPP (0.92) | CLPPCTNNB1TCF7BCL9TCF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | claimed |
| EP-3311841-B1 | ANTICANCER AGENT | PRISM BIOLAB CO LTD (JP) | 2021-07-28 | — | — | EP | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| US-20180185395-A1 | ANTICANCER AGENT | PRISM PHARMA CO., LTD. (JP) | 2018-07-05 | — | — | US | claimed |
| US-20160303137-A1 | DUAL PI3K AND WNT PATHWAY INHIBITION AS A TREATMENT FOR CANCER | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-10-20 | — | — | US | claimed |
| WO-2024113351-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| WO-2024113354-A1 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | NUWACELL BIOTECHNOLOGIES CO., LTD. (CN) | 2024-06-06 | — | — | WO | disclosed |
| EP-2958571-B1 | DNA HYPOMETHYLATING AGENTS FOR CANCER THERAPY | MAIO MICHELE (IT) | 2024-04-10 | — | — | EP | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285498-A1 | TREATMENTS FOR CANCERS HAVING KRAS MUTATIONS | CITY OF HOPE | 2023-09-14 | — | — | US | disclosed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | disclosed |
| US-20080153743-A1 | METHODS RELATING TO THE TREATMENT OF FIBROSIS | UNIVERSITY OF WASHINGTON (US) | 2008-06-26 | — | — | US | disclosed |
| US-20080153743-A1 | METHODS RELATING TO THE TREATMENT OF FIBROSIS | UNIVERSITY OF WASHINGTON (US) | 2008-06-26 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345040-B2 | Reverse-turn mimetics and compositions and methods relating thereto | MYRIAD GENETICS, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-7232822-B2 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-06-19 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | CHOONGWAE PHARMA CORPORATION (KR) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272347-A1 | Differentiation Method | MYADM, EPCAM, MCL1 | CLPP 4481/4885CTNNB1 170/4885TCF7 238/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CLPP 2852/4885CTNNB1 2729/4885TCF7 1631/4885 |
| US-20080153743-A1 | METHODS RELATING TO THE TREATMENT OF FIBROSIS | CFTR, EDNRB, COL1A1 | CLPP 3294/4885CTNNB1 1287/4885TCF7 1888/4885 |
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | CLPP 3298/4885CTNNB1 1181/4885TCF7 2885/4885 |
| US-20070021425-A1 | Reverse-turn mimetics and method relating thereto | WNT1, APC, WNT3 | CLPP 4096/4885CTNNB1 14/4885TCF7 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.